Prophylactic Use of Cranberries in Recurrent Bacterial Cystitis in Women

Recurrent Urinary Tract Infections in Women Clinical Trial

Official title:

Prophylactic Use of Cranberries in Recurrent Bacterial Cystitis in Women: A Randomized, Comparative, Study.

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03032003
• Other study ID #: Cranberries1
• Status: Not yet recruiting
• Phase: N/A
• First received: January 13, 2017
• Last updated: January 23, 2017
• Start date: February 15, 2017
• Est. completion date: May 31, 2018

Study information

• Verified date: January 2017
• Source: University of Thessaly
• Contact: Vasileios Tzortzis, Associated Professor
• Email: tzorvas[@]otenet.gr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To investigate if oral administration of 240mg PAC of cranberries can reduce the number of episodes of acute bacterial cystitis and improve general QoL in women with recurrent bacterial cystitis. In addition, the effect on vagina and rectal flora will studied and the adverse effect profile of the drug will be reported.

Women with ≥3 symptomatic episodes of lower UTIs at the previous year will be recruited from the outpatient population who present to their family physician or specialist with symptomatic recurrent UTI. Informed consent will be obtained from all patients and they will be divided in groups according to their age. Urinary culture, vaginal and rectal swab will be taken from all the patients. Antibiotic treatment will be prescribed (using the drug of choice according to the urine culture and the treating physician choice). Subsequently, they will be randomized to receive combined antibiotic treatment with one capsule of Cysticlean 240mg PAC two times per day or antibiotic treatment with placebo. At 14th day post treatment and after a negative urinary culture patients will continue to receive per os, daily, one capsule of Cysticlean 240mg at bed time for 12 months or placebo respectively.

Study visits will occur at 3rd, 6th , 9th and 12th month treatment phase. A urine collection, vaginal swabs and rectal swab will be taken at study entry and at the month 3, 6, 9 and 12 visits.

Participants will be asked about medication usage, any side effects they may be experiencing at each study visit. If participants develop a UTI at any time during the study, they will be asked to visit the study site within 24 hours.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 160
• Est. completion date: May 31, 2018
• Est. primary completion date: March 31, 2018
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• Negative urine culture

• At least 3 UTI's within 12 months prior to study entry

Exclusion Criteria:

• Anatomic abnormalities of the urinary tract

• Use of investigational drugs within 30 days prior to study entry

• Current use of warfarin

• Allergy or intolerance of cranberry products

• > 50 ml of residual urine (measured by US)

• Use of indwelling catheter

• uncontrolled diabetes

• creatinine > 250 mmol/l,

• Symptomatic vaginitis

• Pregnant or breastfeeding

Related Conditions & MeSH terms

• Cystitis
• Recurrent Urinary Tract Infections in Women
• Urinary Tract Infections

Intervention

Other:
• Cysticlean
2 BID for 15 days
• Placebo
2 BID for 15 days

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
University of Thessaly

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Effectiveness of the use of Cranberries in the prevention of the recurrent UTIs is women.	Follow up with urinary cultures will be evaluated for Cranberries affection in UTIs	12 months